BioNTech BNTX · NASDAQ
$86.92 -0.70% (-$0.61)
Summary
31 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: 10.2B € against 359.8M €.
- The share price is below the Bulios Fair Price.
- Out of every 100 EUR of revenue, 20 EUR is left as free cash.
What to watch
- Revenue fell by 46% a year over the last 3 years.
- The company made a loss over the last 12 months.
- Analysts expect revenue to fall by 35% this fiscal year.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 42% a year over 5 years. Over the last 3 years it fell by 46% a year. For the next fiscal year analysts expect revenue to fall by 35%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of 1.48B €.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 20
- Hold 4
- Sell 0
Today's price within the analysts' price targets
The average target of $121.83 is 40% above today's price. 83% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Other Sales 100%
By region
- UNITED STATES 63%
- GERMANY 26%
- IRELAND 11%
- Rest of the World 0.4%
Other Sales brings in 100% of revenue.
Segments in detail